DexamethasoneInsulin resistance and off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1911卷 / 1期

关键词：

D O I：

10.1007/s40278-022-17470-3

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：173 / 173

相关论文

共 50 条

[1] BamlanivimabAcquired resistance and off-label use: case report
Reactions Weekly, 2023, 1938 (1) : 302 - 302
[2] Inotuzumab ozogamicinDevelopment of resistance and off-label use: case report
Reactions Weekly, 2019, 1783 (1) : 147 - 147
[3] DalbavancinDrug-resistance and off-label use: case report
Reactions Weekly, 2019, 1734 (1) : 170 - 170
[4] Multiple drugsDrug resistance and off-label use : case report
Reactions Weekly, 2022, 1917 (1) : 387 - 387
[5] Ixazomib/venetoclaxDrug resistance and off-label use: case report
Reactions Weekly, 2022, 1927 (1) : 308 - 308
[6] Azacitidine/olaparibDrug resistance and off-label use: case report
Reactions Weekly, 2022, 1904 (1) : 92 - 92
[7] AntineoplasticsTreatment failure, drug resistance and off-label use: case report
Reactions Weekly, 2022, 1931 (1) : 85 - 85
[8] ErtapenemAcquired drug resistance following off-label use: case report
Reactions Weekly, 2022, 1909 (1) : 245 - 245
[9] AntineoplasticsDevelopment of resistance, lack of efficacy and off-label use: case report
Reactions Weekly, 2021, 1866 (1) : 44 - 44
[10] Brigatinib/crizotinib/lorlatinibDrug resistance and off-label use: case report
Reactions Weekly, 2020, 1802 (1) : 80 - 80

← 1 2 3 4 5 →